MDx/CDx Focus: Abbott CDx for Janssen, Pharmacyclics' Lymphoma Drug; Covance, M2Gen Collaborate
February 27, 2013
MDx/CDx Focus: Abbott CDx for Janssen, Pharmacyclics' Lymphoma Drug; Covance, M2Gen Collaborate
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Covance, M2Gen Aim to Improve Patient Recruitment for Oncology Trials
February 26, 2013 / GenomeWeb Daily News - Janssen Biotech, Pharmacyclics Explore Abbott FISH Technology as CDx for CLL
February 21, 2013 / GenomeWeb Daily News - Moffitt's M2Gen Launches Trial Cohort Selection Service Based on Patient Gene Expression Database
February 17, 2012 / BioInform - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - MDx/CDx Focus: Abbott, Epizyme Advance CDx for Novel Leukemia Drug; Segeene, Selventa Develop MDx
April 24, 2013 / Pharmacogenomics Reporter